|  |  |
| --- | --- |
|

|  |
| --- |
| Level 1A, City TowerPiccadilly PlazaManchesterM1 4BTTel: 0845 003 7780Fax: 0845 003 7784[www.nice.org.uk](https://web.nhs.net/owa/redir.aspx?C=3n_hM-iQXUySdq6xVhgPwDAQgTtBD9BILV0DXfRv9Isay-X-GhXxgICHbvysQgvyWxwhH8_yIww.&URL=http%3a%2f%2fwww.nice.org.uk) |

 |
| Dear Consultee and CommentatorFollowing on from the review decision published in November 2012 to update technology appraisal TA143 adalimumab, etanercept and infliximab for treating ankylosing spondylitis and TA233 golimumab for treating ankylosing spondylitis, I felt it helpful to write and advise you of the draft appraisal timelines we have planned for your information. A draft scope is expected to be issued for consultation in early July 2013, with the final scope issued in approximately mid October 2013 when we will also write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2014.These dates remain provisional at this stage and are subject to change.Best Wishes**Anthony Gildea**Scheduling Project Manager – Planning and OperationsNational Institute for Health and Care ExcellenceLevel 1A | City Tower | Piccadilly Plaza | Manchester M1 4BT | United KingdomTel: 0161 219 3849 |